FINANCIAL PERFORMANCE

Expenses of the Anticancer Fund and Reliable Cancer Therapies in 2015 **

**Anticancer Fund expenses, which covers all project costs of the Swiss, non-profit organization Reliable Cancer Therapies managed by the Anticancer Fund.

ANTICANCER FUND EXPENDITURE for 2015 was € 2,222,438.

Amount spent on

- **INFORMATION**: € 437,726
  - This expenditure covers two main areas:
    1. website costs, including updating information and adding new information
    2. the costs of maintaining our patient support via info@anticancerfund.org

- **COMMUNICATION AND FUNDRAISING**: € 206,375
  - This includes a dedicated full-time fundraising employee.

- **GENERAL SUPPORT**: € 142,500
  - This covers the general administrative support at the Anticancer Fund.

- **RESEARCH PROJECTS**: € 1,203,628
  - The research projects are managed by our in-house team of scientists and medical doctors in close collaboration with external researchers worldwide.

- **KNOWLEDGE BUILDING**: € 232,209
  - This covers – amongst others – all investigational costs related to the Hepatocellular Carcinoma project, Aspirin trial in Colorectal cancer and trial in Pancreatic cancer

Total amount spent by the Anticancer Fund: € 2,200,000 well spent in the fight against cancer!
1. Research Projects

**MAIN ACTIVITIES**

**ANNUAL IMPACT SHEET 2015**

[Image: Anticancer Fund logo]

Our vision

- The Anticancer Fund is dedicated to expanding the range of treatment options available to patients, regardless of their commercial value.

Our dual mission

- Developing promising cancer treatments that are currently neglected and bringing the most valuable treatments to the patient as quickly as possible.
- Providing free comprehensive, evidence-based information about cancer treatments.

NEW IN 2015

Projects

<table>
<thead>
<tr>
<th>Country</th>
<th>Project area</th>
<th>Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>Germany</td>
<td>GBM</td>
<td>€ 299,276</td>
</tr>
<tr>
<td>Germany</td>
<td>NSCLC</td>
<td>€ 468,999</td>
</tr>
</tbody>
</table>

Publications - ReDO - Repurposing Drugs in Oncology

The Repurposing Drugs in Oncology (ReDO) project is a collaboration with the US not-for-profit organisation Global Cures. The aim of the project is straightforward – to identify a range of existing non-cancer drugs which show strong evidence of anti-cancer activity and which have the potential for clinical use. The value of this concept has been elaborated in an interesting article ‘Drug repurposing in oncology – patient and health systems opportunities’ in *Nature Reviews Clinical Oncology* (doi:10.1038/nrclinonc.2015.169).

There is a broad spectrum of drugs that the ReDO project has identified, many of them available as cheap generics, including antibiotics, antifungals and antiparasitics. Taking evidence from a variety of sources, the ReDO project has reviewed, summarized the results and published articles on Clarithromycin (doi:10.3332/epidem.2015.101), Itraconazole (doi:10.3332/epidem.2015.513), Triacranoxolone (doi:10.3332/epidem.2015.521) and Nitroglycerin (doi:10.3332/epidem.2015.568) in the *ecancermedicalscience*, the open access peer-reviewed cancer journal founded by the European Institute of Oncology. These articles were viewed more than 7,200 times on www.ecancer.org. These publications are part of a continuing collaboration with ecancer, the leading oncology channel committed to improving cancer communication and education with the goal of optimizing patient care and outcomes.

ACF-supported research projects are currently scheduled to include over 640 patients:

- Endometrial cancer: 10 patients
- Colorectal cancer: 10 patients
- Lung cancer: 146 patients
- Liver cancer: 16 patients
- Breast cancer: 469 patients
- Osteosarcoma: 26 patients
- Melanoma: 12 patients
- Glioblastoma: 10 patients
- Optic-pathway glioma: 35 patients
- All cancer types: 56 patients

For a detailed list of our projects, contact us or consult our website: [www.anticancerfund.org](http://www.anticancerfund.org)

ANNUAL IMPACT SHEET 2015

Page 2/4

www.anticancerfund.org

NEW IN 2015

**Country**  | **Project area**  | **Budget**  
--- | --- | ---  
Germany  | GBM  | € 299,276  
Germany  | NSCLC  | € 468,999  

**Partnership with OvaCure and Van de Velde**

After a successful round table conference on ‘adoptive TIL transfer-therapy in melanoma and ovarian cancer’ in June 2014, a partnership between OvaCure (a Danish non-profit organization focused on the fight against ovarian cancer) and the Anticancer Fund was established. The Anticancer Fund is the scientific strategy partner at OvaCure and member of the OvaCure Scientific and Clinical Advisory Board. [www.ovacure.org](http://www.ovacure.org)

In June 2015, a partnership between Belgian company Van de Velde nv, one of the market leaders in luxury lingerie, and the Anticancer Fund was formed which will lead to the publication of the breast cancer guide for patients. This guide for patients will explain about the non-conventional treatment options for breast cancer patients and will be available in 2016.

ANNUAL IMPACT SHEET 2015

Page 3/4

www.anticancerfund.org